Monday, 25 May 2026 11:00 PM
Advertorial
Consumer-focused analysis reviews Tonum Health's stimulant-free Motus supplement, disclosed ingredient doses, open-label trial limitations, refund terms, and berberine interaction considerations.
WEST PALM BEACH, FL / ACCESS Newswire / May 25, 2026 / Disclaimers: This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products. Disclosure is provided in accordance with FTC 16 CFR Part 255. The statements in this article have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease. Information provided is for general informational purposes and does not constitute medical advice. Readers experiencing symptoms or considering changes to their health regimen should consult a licensed healthcare professional. Individual results vary.
Tonum Motus 2026 Report Examines Human Study Data, Berbevis Formula, and Non-Prescription Metabolic Support Trends
TL;DR: Motus is a stimulant-free metabolic supplement built around 500mg Berbevis® - a berberine-phospholipid phytosome from Indena S.p.A. - plus Siliphos®, Alpha-Lipoic Acid, Nicotinamide, and Taurine. The brand's open-label, 100-participant human study reported average weight loss of 10.4% at 24 weeks with favorable body-composition findings. That result is meaningful. It also comes from a single non-placebo-controlled trial. The NCCIH separately notes that berberine evidence for weight loss remains inconclusive at the population level. Both facts belong in the same sentence before checkout.
Quick Verification Snapshot - As of May 2026
Quick answer: Motus is sold exclusively through the official Tonum website at $59.99 per bottle (120 capsules, 30-day supply at 4 capsules daily). The formula discloses five named ingredients at individual stated doses: Berbevis® 500mg, Siliphos® 550mg, Alpha-Lipoic Acid 300mg, Nicotinamide (Vitamin B3) 850mg, and Taurine 625mg. A 30-day return policy covers unopened, factory-sealed bottles only. Opened bottles are not eligible for a refund per the brand's published terms.
Product: Motus® by Tonum Health (division of Prostasis, LLC)
Company address: 400 North Flagler Drive, West Palm Beach, FL 33401
Contact: [email protected] | [email protected]
Price: $59.99/bottle (1-month); Consistency Plan (3-month, free shipping); Commitment Plan (6-month, 10% off + free shipping)
Serving size: 4 capsules daily with food
Capsule count: 120 capsules per bottle (30-day supply)
Refund policy: 30-day guarantee on unopened bottles only; opened bottles ineligible
Clinical trial registry: NCT07152470 (ClinicalTrials.gov, sponsored by Prostasis, LLC dba Tonum Health)
Key ingredient trademarks: Berbevis® (Indena S.p.A.), Siliphos® (Indena S.p.A.)
Stimulants: None disclosed on label
Prescription required: No
Verified official website: tonum.com
Buyer takeaway: The 30-day return window applies only to factory-sealed bottles. Once any bottle is opened, refund eligibility ends regardless of how much product was used. Buyers evaluating a multi-month plan should understand that distinction before enrolling - especially since meaningful body-composition changes typically take 8 to 12 weeks to develop.
What Is Motus and Who Makes It?
Quick answer: Motus is a five-ingredient oral supplement made by Tonum Health, a division of Prostasis, LLC in West Palm Beach, Florida. According to the brand, the formula was developed to support fat metabolism while preserving lean muscle mass - positioning it as a non-prescription option for adults who prefer not to use injectable GLP-1 medications or stimulant-based fat burners.
Per the official website, Tonum Health was founded in 2018 as a division of Prostasis, a company the brand describes as built by pharmaceutical and nutraceutical scientists. The company states the formula was developed through nearly a decade of research, including pre-clinical and human studies conducted in collaboration with Duke University researchers. That collaboration is brand-attributed; independent confirmation through public university records was not available at the time of this writing.
The brand's Chief Scientific Officer, Nicholas Moore, PhD, is quoted in company press materials stating that Motus was designed to support fat metabolism without loss of lean mass "using ingredients that work in harmony with the body's natural systems." The company's founder is quoted separately describing the formula as "the result of rigorous research, AI-powered formulation, and a commitment to science-first natural wellness."
What sets Motus apart from many weight management supplements isn't the ingredient names - it's the ingredient forms. The brand does not use commodity berberine hydrochloride or standard milk thistle extract. According to the brand's published materials and the product label, Motus contains Berbevis® and Siliphos® - both registered trademarked phytosome formulations licensed from Indena S.p.A. of Italy. Indena has published its own clinical and pharmacokinetic research on both ingredients. That distinction carries real implications for bioavailability, which the next section addresses directly.
Motus is made by Tonum Health through Prostasis, LLC. Buyers should verify current company contact details, pricing, and return terms directly at tonum.com before purchasing, since all terms are subject to change per the brand's published policies.
Disclosure: If you buy through this link, a commission may be earned at no extra cost to you.
The Five Ingredients - What the Doses and Forms Actually Mean
Most buyers assume ingredient names alone tell the story. They don't. The form of an ingredient - not just the name - determines how much of the active compound the body can absorb and use. Here is what the Motus label discloses, and what published research says about each ingredient at the disclosed dose.
Berbevis® (Berberine Phytosome) - 500mg
According to the brand, Berbevis® is the formula's primary active. It is a berberine-phospholipid complex manufactured by Indena S.p.A. using proprietary phytosome technology. Standard berberine hydrochloride - the form found in most commodity berberine products - has notoriously poor oral bioavailability. Published pharmacokinetic research on Berbevis® from Indena's own program shows the phytosome form delivers meaningfully higher systemic berberine exposure (higher AUC values on a molar basis with observed dose linearity) compared to standard berberine chloride in healthy volunteers. Published comparative data from commercial supplement brands indicates berberine phytosome forms deliver up to five times higher bioavailability than standard HCL when taken on an empty stomach.
Per Indena's published data, a human randomized, double-blind, placebo-controlled trial with Berbevis® demonstrated that 60 days of supplementation supported measured metabolic markers related to glucose regulation in individuals with challenged fasting glucose, with favorable trends in total cholesterol, triglycerides, cholesterol/HDL ratio, ApoB/ApoA ratio, visceral fat, total fat mass, and waist circumference in the supplemented group.
The important counterweight: the National Center for Complementary and Integrative Health - part of the National Institutes of Health - maintains that evidence on berberine for weight loss overall is "not conclusive." While some smaller controlled trials have suggested modest benefit, published meta-analyses report that standard berberine HCL typically produces weight loss clustering around 1-3 kilograms over 8-12 weeks. The American Academy of Family Physicians has characterized standard berberine as lacking the rigorous evidence base required to call it a proven weight-loss agent. The Berbevis® phytosome form has its own published RCT data that standard berberine HCL does not, and that distinction matters when reading NCCIH's general berberine assessment. Reasonable physicians can and do disagree about the magnitude and durability of benefit from this ingredient class.
Drug interaction note - read this before buying: Berberine in all forms, including Berbevis®, inhibits liver enzymes CYP2D6, CYP3A4, and CYP2C9, and also inhibits P-glycoprotein. This can raise blood concentrations of medications that rely on these pathways for clearance. The highest-risk combinations documented in published literature include anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran), diabetes medications (metformin, insulin, sulfonylureas), CYP3A4-metabolized statins (simvastatin, lovastatin), antihypertensives, and immunosuppressants (cyclosporine, tacrolimus). Berberine is also contraindicated during pregnancy and breastfeeding. Anyone on prescription medications should review this interaction profile with a pharmacist or physician before starting this supplement.
Siliphos® (Silybin Phytosome, Milk Thistle) - 550mg
Per the brand's published materials, Siliphos® is a silybin-phosphatidylcholine phytosome also manufactured by Indena S.p.A. Standard milk thistle extracts contain silymarin, of which silybin is the primary bioactive. The problem with standard milk thistle: silybin's oral bioavailability from crude extracts is low and inconsistent. Published pharmacokinetic studies consistently show that silybin phytosome formulations like Siliphos® raise plasma silybin levels several-fold compared to conventional silymarin. In short human trials documented in the peer-reviewed literature, silybin phytosome formulations have been associated with measurable reductions in liver enzymes (ALT, AST) and hepatic fat in individuals with mildly elevated markers and early non-alcoholic fatty liver disease.
The brand positions liver health as a critical upstream variable in fat metabolism - the liver is the body's primary fat-processing organ - and frames Siliphos® as supporting that metabolic infrastructure. The biological connection between liver function and weight management is well-grounded. Whether Siliphos® at 550mg produces measurable body-composition benefit in adults with healthy baseline liver function specifically has not been established outside the Motus trial data.
Nicotinamide (Vitamin B3) - 850mg
According to the brand, nicotinamide is included to support cellular energy metabolism. It is a co-factor in NAD+ biosynthesis and plays a recognized role in cellular energy production. The 850mg dose substantially exceeds the 16mg Dietary Reference Intake for niacin, though nicotinamide does not carry the vascular flushing risk associated with nicotinic acid. The NIH Office of Dietary Supplements notes that high-dose nicotinamide may affect glucose metabolism, though effects specifically on body weight in healthy adults remain less definitively characterized at the population level.
Alpha-Lipoic Acid - 300mg
The brand states that alpha-lipoic acid is included to support energy production and glucose utilization. ALA is a mitochondrial co-factor and antioxidant with a published evidence base in the context of insulin sensitivity and oxidative stress reduction. Published research shows evidence that ALA supplementation can modestly support metabolic markers related to glucose handling in certain populations. The 300mg dose falls within the range examined in published trials.
Taurine - 625mg
Per the brand's materials, taurine supports cellular energy and metabolic function. It is a conditionally essential amino acid involved in bile salt conjugation, cardiovascular function, and cellular hydration. The 625mg dose sits within commonly studied ranges. The brand positions taurine around supporting steady energy without stimulants - consistent with taurine's published roles in cellular metabolism.
Motus uses phytosome-enhanced Berbevis® and Siliphos® rather than commodity extracts. The bioavailability distinction between Berbevis® and standard berberine HCL is supported by published pharmacokinetic data from Indena. Whether that translates to superior weight management outcomes in large independent randomized trials is a question the existing research has not yet definitively answered.
What the Brand's Human Study Actually Shows - and What the Design Means
Quick answer: Tonum Health reported results in August 2025 from an open-label, 100-participant, six-month human study of Motus. The study showed average weight loss of 5.7% at 12 weeks across all participants, rising to 10.4% at 24 weeks among the 40 participants in the extension phase, with the brand reporting favorable body-composition findings suggesting lean-mass preservation. The study is registered at ClinicalTrials.gov (NCT07152470, sponsored by Prostasis, LLC dba Tonum Health). Results were presented at Obesity Week 2025. No results are posted in the registry result field at this time; all outcomes cited here are brand-reported. This is a single open-label study without a placebo control group - a design limitation buyers should understand before treating these numbers as definitive proof of efficacy.
The study enrolled 100 adults aged 25-68 with BMI of 25 or above in the United States. Participants were not required to change their diet or exercise habits - however, results were meaningfully different based on what participants actually did during the study. The brand reports a clear dose-response pattern when participants were grouped after the fact by self-reported lifestyle behaviors: those following a healthy diet and exercising four or more times per week averaged 14.83% weight loss; those with average diet and two to three exercise sessions per week averaged 10.02%; and those with average diet and no exercise averaged 8.92%.
Per the brand's press materials, the study was conducted in collaboration with Duke University researcher Jon Campbell, PhD, and builds on prior pre-clinical research the brand reports showed Motus supporting fat oxidation and energy expenditure independent of food intake reduction, per the company's preclinical data.
What buyers need to understand about open-label design: participants knew they were taking the supplement. That knowledge alone can increase motivation to track food, move more, and engage with a health goal. Without a placebo control arm, it is not methodologically possible to isolate how much of the observed weight loss came from the formula versus the study enrollment effect, lifestyle behavior shifts, or participant motivation during the trial period. An open-label study is a meaningful starting point in an evidence hierarchy - but it is not equivalent to a double-blind, randomized, placebo-controlled trial.
Per the brand's reported data, if replicated in an independent, placebo-controlled trial, a 10.4% average loss at 24 weeks would hold significance in weight-management research contexts. Published pharmacology literature often treats 5% loss as the threshold for metabolic benefit and 10% as a marker of meaningful change for mobility and metabolic markers. The brand-reported body-composition findings suggesting lean-mass preservation are also worth noting, since muscle loss is a documented concern with many weight-management approaches.
The Tonum human study represents meaningful brand-funded evidence in a category where most supplements have no human trial data at all. The open-label design is a genuine limitation that does not invalidate the data but does mean results require independent replication in placebo-controlled trials to confirm. Treat it as a promising signal, not settled proof.
What Most Buyers Check Too Late: Three Facts About This Category
Weight management is one of the most aggressively marketed supplement categories in the United States. The skeptic bar is high, and for good reason. Three facts about this category apply directly to any Motus purchasing decision - and most buyers discover them after opening their first bottle.
First: The NCCIH position on berberine is not a ringing endorsement
The National Center for Complementary and Integrative Health states that while berberine is being studied for its effects on diabetes risk factors and heart disease markers, evidence for weight loss specifically remains "not conclusive." Standard berberine HCL typically shows 1-3 kilograms of loss over 8-12 weeks in published RCTs - a far cry from the 10.4% reported in Tonum's open-label study. The Berbevis® phytosome form has its own Indena-sponsored clinical data that standard berberine HCL does not, and that distinction is important context. But broad berberine research should not be read as validation of the Motus-specific outcomes, and Tonum's trial should not be treated as settled science absent independent placebo-controlled replication.
Second: The refund policy is more restrictive than most buyers expect
The brand's published refund policy provides 30 days from purchase to return unopened, factory-sealed bottles. Opened bottles with seals removed are ineligible. For a category where meaningful body-composition changes typically emerge over 6-8 weeks of consistent use, the 30-day unopened window means a buyer who opens their first bottle on day one and uses it daily has moved outside return eligibility well before seeing any results. This is not unusual in the supplement space, but it is critical to understand before committing to a multi-month plan.
Third: Injectable GLP-1 medications have a substantially larger clinical evidence base
The brand's own marketing compares Motus favorably to injectable GLP-1 medications. That framing is reasonable context for a non-prescription option. It should also be read clearly: injectable GLP-1 agonists have been studied in large, multi-year, multi-thousand-participant, randomized, placebo-controlled trials showing average weight losses of 15-22% in approved use populations. The Motus open-label study is 100 participants over 6 months with no placebo group. The two evidence bases are not equivalent in scale or design. No honest evaluation of this product should suggest otherwise.
Motus is transparently formulated with phytosome-grade ingredients and brand-funded human study data. Buyers need to weigh those genuine strengths against the real limitations of a single open-label trial, the NCCIH's position on berberine broadly, and the refund policy mechanics before making a purchasing decision.
Is the Berbevis® Phytosome Form Actually Different From Regular Berberine?
This question matters more than most buyers realize. Berberine's fundamental problem in standard form is not efficacy - it is bioavailability. Standard berberine hydrochloride is poorly and inconsistently absorbed in the gut. Published pharmacokinetic research consistently shows that much of an oral berberine dose in standard form does not reach systemic circulation in useful quantities. That is why RCT findings with commodity berberine HCL cluster at modest outcomes even at gram-level doses.
Berbevis® addresses this through a different delivery mechanism. Per Indena's published technical documentation, the phytosome technology binds berberine to a pea protein phospholipid matrix using Berberis aristata raw extract - which is more soluble than pure berberine - with grape seed extract included as a gastrointestinal tolerability protectant. Published pharmacokinetic data from Indena shows Berbevis® delivers meaningfully higher AUC on a molar basis compared to berberine chloride in healthy volunteers, with observed dose linearity indicating predictable absorption scaling.
The clinical implication: published Indena-sponsored human RCT data on Berbevis® specifically - distinct from general berberine RCT data - shows that 60-day supplementation supported measured metabolic markers related to glucose regulation versus placebo, with favorable trends in visceral fat, total fat mass, waist circumference, and lipid markers. These are ingredient-level outcomes from a controlled trial design that standard berberine HCL literature does not have at an equivalent quality level.
The distinction is pharmacokinetically documented, not a marketing assertion. When the NCCIH says berberine evidence is inconclusive, that assessment is based primarily on standard HCL research. Whether Berbevis®'s improved bioavailability profile translates to reliably superior weight-management outcomes in large, independent trials remains an open research question. But it is not the same compound in the same form as what most general berberine commentary addresses.
Comparing Motus to commodity berberine HCL products on price is not an apples-to-apples comparison. Berbevis® has published pharmacokinetic data supporting superior bioavailability. Whether that translates to superior real-world outcomes at the 500mg dose in Motus requires further independent research to confirm definitively.
What "Food Noise" Means - and Why Tonum Built Around Reducing It
Quick answer: "Food noise" is the term Tonum uses to describe the constant, intrusive mental preoccupation with food - cravings, snack impulses, and the recurring mental pull toward eating that makes calorie management feel like willpower-intensive work. The brand positions Motus as supporting reduced food noise, which is also one of the primary mechanisms cited for GLP-1 medications' appetite effects. This framing reflects a real behavioral pain point for buyers managing weight, and it connects to the ingredient-level mechanisms the brand attributes to the formula.
Per the brand's published materials, Motus is designed to support balanced hunger and fullness signaling, making it easier to stay aligned with weight management goals without constant food preoccupation. User-reported outcomes cited on the brand's website include fewer cravings, reduced obsession with food between meals, and easier portion management. These are self-reported outcomes from brand-presented materials - not independently verified clinical endpoints - and are presented here as brand-attributed user reports, not publisher-confirmed results. Individual results vary. Outcomes reported by individual users may not be typical and do not represent expected results for all users.
Why this matters for the buying decision: most weight management supplements target one mechanism - usually thermogenesis or appetite suppression. Motus's five-ingredient architecture targets multiple pathways simultaneously: metabolic marker support (Berbevis®), liver-function infrastructure (Siliphos®), cellular energy metabolism (Nicotinamide, ALA, Taurine), and the appetite-signaling dimension the brand frames as food noise reduction. Whether all five pathways work synergistically in the way the brand describes requires controlled trial data beyond what currently exists publicly.
"Food noise" reduction is a legitimate behavioral outcome that matters for long-term weight management adherence. Tonum's positioning around this mirrors the mechanism that makes GLP-1 medications compelling for many users. The brand attributes this effect to the formula; independent controlled evidence specifically isolating that outcome in Motus users is not yet publicly available.
Does Motus Work?
What the Available Evidence Actually Suggests
Quick answer: Motus contains five ingredients with published research supporting their individual roles in metabolic function - two of which use phytosome forms with ingredient-level RCT data that commodity versions of those ingredients do not have. The brand's own human study reports favorable results at 24 weeks, with the limitations of open-label design acknowledged throughout. Whether Motus produces similar results for any given buyer depends on that buyer's baseline metabolic health, consistency, lifestyle habits, and individual biology.
Per the brand, Motus is designed to complement existing lifestyle habits rather than replace them. The human study showed a clear pattern: more lifestyle engagement produced larger outcomes. The group with healthy diet and regular exercise averaged 14.83% weight loss; the group with average diet and no exercise averaged 8.92%. The company states the formula works by supporting the body's own metabolic pathways - not by overriding energy balance through stimulant-driven appetite suppression alone.
The brand also highlights lean-mass preservation as a distinguishing feature. The company reports favorable body-composition findings from the human study, with the brand attributing the majority of observed weight loss to fat mass rather than lean mass. The brand's pre-clinical research, presented at Obesity Week 2025 by Jon Campbell, PhD, also suggests Motus may support fat oxidation and energy expenditure through mechanisms independent of food intake reduction, per the company's preclinical data. If confirmed in independent controlled trials, that would distinguish Motus from stimulant-based fat burners that operate primarily through appetite suppression.
Per the disclosed label, Motus is stimulant-free. The five disclosed ingredients - Berbevis®, Siliphos®, Alpha-Lipoic Acid, Nicotinamide, and Taurine - are not stimulant compounds. Buyers who have experienced tolerance buildup, sleep disruption, or cardiovascular concerns with stimulant-based weight-management products may find that relevant.
The ingredient-level evidence supports the mechanisms the brand claims. The human study data is promising but comes from a single open-label trial. Modest to meaningful metabolic support is the plausible outcome range for eligible buyers. Expectations calibrated to a research-backed supplement - not a pharmaceutical-grade drug - represent the honest framing.
Motus as a Natural Alternative to GLP-1 Injectables - What the Comparison Actually Means
Searches for "natural alternative to GLP-1" and "natural Ozempic alternative" have grown substantially as concerns about injectable medication costs, side effects, and access have increased. Tonum positions Motus directly in this conversation, and the comparison is worth examining honestly rather than dismissing or overclaiming.
The brand frames Motus as differentiated from injectable GLP-1 medications on several specific dimensions. First, per the brand, Motus is designed to support fat loss while preserving lean muscle mass - a meaningful concern, as lean mass reduction has been documented in some GLP-1 medication populations in published research. Second, per the brand, Motus is stimulant-free and non-injectable - no prescription, no needles, no pharmacy coordination. Third, the brand highlights that weight regain after stopping GLP-1 medications is documented in published research, and positions Motus as a longer-term metabolic support option. All three of these are legitimate differentiating points grounded in published literature. They are also brand-framed positions, not independent clinical verdicts.
What the comparison does not change: injectable GLP-1 agonists like semaglutide and tirzepatide have been studied in tens of thousands of participants across multi-year, multi-country, randomized placebo-controlled trials, showing average weight losses of 15-22%. The Motus human study is 100 participants, 6 months, open-label, with no placebo control group. The evidence bases are not equivalent in scale or rigor. Buyers considering Motus as an alternative to a GLP-1 medication they are currently taking should discuss that decision with their prescribing physician before making any changes to their treatment plan.
Motus is a legitimate non-prescription, non-injectable option in the "natural GLP-1 alternative" search category. The brand's differentiation points are grounded in published literature. The comparison should not be read as evidence equivalence - the two categories do not yet share a comparable evidence base in size or design.
Pricing, Plans, and What to Confirm Before Enrolling
Motus is sold exclusively through the official Tonum website via an auto-delivery subscription model. The brand does not currently list the product through third-party retailers. Per the official website, current pricing is as follows: a single bottle contains 120 capsules - a 30-day supply at the recommended four capsules daily - at $59.99. The Consistency Plan covers three months of supply with free shipping. The Commitment Plan covers six months with 10% off the per-bottle price plus free shipping. The brand also notes HSA/FSA eligibility messaging on qualifying purchases, though buyers should confirm eligibility with their own plan administrator since HSA/FSA coverage for dietary supplements varies by plan.
The auto-delivery model allows pausing or canceling at any time per the brand's published terms. Before enrolling in any multi-month plan, three things are worth confirming directly with the brand: whether the subscription can be paused rather than just canceled, the exact process for canceling before the next shipment date, and whether the 30-day return policy covers the current subscription period or only the initial order. Contact the brand at [email protected] to clarify before enrolling.
The six-month Commitment Plan offers the best per-bottle price, but commits buyers beyond the single-bottle refund window. Anyone who has not tried Motus before should start with a single bottle to evaluate personal response before subscribing to a multi-month plan.
Who Should and Should Not Consider Motus
The brand states on the official website that Motus is intended for daily use as directed - with medical review recommended for anyone pregnant, nursing, managing a medical condition, or taking prescription medications. The brand specifically identifies pregnancy and nursing as situations requiring healthcare provider consultation before use.
Beyond the brand's published guidance, the drug interaction profile of berberine in all forms - including Berbevis® - warrants specific attention. The highest-risk combinations documented in published literature include anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran - case reports document changes in INR after berberine initiation in warfarin users), diabetes medications (metformin, insulin, sulfonylureas - combined use without blood glucose monitoring can result in hypoglycemia), immunosuppressants with narrow therapeutic windows (cyclosporine, tacrolimus - berberine inhibition of CYP3A4 and P-glycoprotein can raise drug concentrations significantly), CYP3A4-metabolized statins (simvastatin, lovastatin), and antihypertensive medications. The NCCIH specifically notes that berberine is likely unsafe during pregnancy or breastfeeding due to documented potential for harmful effects in infants.
The buyer profile for whom Motus appears most appropriately positioned: healthy adults aged 25 and above with BMI of 25 or above who are not on prescription medications with the above interaction profiles, who are not pregnant or nursing, and who are looking for a non-prescription, non-injectable metabolic support option to complement existing lifestyle habits. Anyone outside those parameters should complete a pharmacist-reviewed medication check before starting.
Anyone taking anticoagulants, diabetes medications, immunosuppressants, or CYP3A4-metabolized statins should complete a pharmacist interaction review before starting this or any berberine-containing product. This is not generic disclaimer language - it is a specific, clinically documented interaction risk that applies to this formula.
What Honest Buyers Want to Know: 10 Direct Questions Answered
What is Motus and what is it supposed to do?
Motus is a five-ingredient metabolic support supplement made by Tonum Health (Prostasis, LLC). The brand positions it to support fat metabolism, help preserve lean muscle mass during weight management, and reduce "food noise" - the persistent mental pull toward eating between meals. The formula is built around two phytosome-grade ingredients from Indena S.p.A. (Berbevis® and Siliphos®) alongside Alpha-Lipoic Acid, Nicotinamide (Vitamin B3), and Taurine. It is stimulant-free and does not require a prescription. The recommended dose is four capsules daily with food from a 120-capsule bottle priced at $59.99 per month.
Does Motus have clinical evidence behind it?
The brand reports results from a 100-participant, six-month, open-label human clinical study registered at ClinicalTrials.gov (NCT07152470, sponsored by Prostasis, LLC dba Tonum Health). The study showed average weight loss of 5.7% at 12 weeks and 10.4% at 24 weeks in the 40-participant extension group, with the brand reporting favorable body-composition findings suggesting lean-mass preservation. Results were presented at Obesity Week 2025. The study design is open-label with no placebo control group - a meaningful methodological limitation. No results are posted in the registry result field at this time. At the ingredient level, Berbevis® has published Indena-sponsored RCT data showing benefits for measured metabolic markers, lipids, and body composition versus placebo. Both the study-level and ingredient-level evidence are meaningful; neither is a substitute for independently replicated, double-blind, placebo-controlled trial data.
Is Motus safe for people taking diabetes medications?
Buyers taking diabetes medications - metformin, insulin, sulfonylureas, or SGLT2 inhibitors - should consult a physician or pharmacist before using Motus. Berberine has independent blood glucose-lowering activity through multiple mechanisms including AMPK activation and enhanced glycolysis. Combined use with diabetes medications without blood glucose monitoring can increase the risk of hypoglycemia. The brand's published FAQ recommends consulting a healthcare professional for anyone with a medical condition or taking medication. The NCCIH also specifically flags berberine's potential interaction with diabetes medications in published consumer guidance. This is a specific, clinically documented interaction risk - not boilerplate.
What is the refund policy for Motus?
Per the brand's published refund policy at tonum.com, a 30-day money-back guarantee applies to unopened, factory-sealed bottles only. Any bottle with the seal removed is ineligible regardless of how much product was used. The brand describes its auto-delivery subscription as "pause or cancel anytime." Buyers who open their first bottle on delivery and use it daily for 30 days will have consumed the full bottle by the time the return window closes - with no refund available. Buyers who want to confirm current terms before ordering should contact the brand directly at [email protected].
What are the ingredients in Motus and at what doses?
Per the product label and brand sources, Motus contains these five ingredients per four-capsule serving: Berbevis® (Berberine Phytosome, Indena S.p.A.) 500mg; Siliphos® (Silybin Phytosome, Milk Thistle, Indena S.p.A.) 550mg; Alpha-Lipoic Acid 300mg; Nicotinamide (Vitamin B3) 850mg; Taurine 625mg. The brand discloses individual doses for each ingredient rather than hiding amounts in a proprietary blend. In a category where proprietary blends frequently obscure what buyers are actually getting per capsule, that level of label transparency is worth noting.
Is Motus a GLP-1 medication or a prescription drug?
No. Motus is a dietary supplement regulated under DSHEA, not a prescription medication and not a GLP-1 receptor agonist. It contains no semaglutide, tirzepatide, or any pharmaceutical GLP-1 compound. The brand's comparison to GLP-1 medications in its marketing describes how the approaches differ across specific dimensions - it does not claim Motus functions as a pharmaceutical equivalent. Buyers currently taking GLP-1 medications who want to add or transition to Motus should discuss that decision with their prescribing physician before making any changes to their treatment plan.
How long does it take to see results with Motus?
Per the brand's official website, some users report improved energy and metabolic support within the first few weeks. Body-composition changes typically take longer - the brand's guidance points to 6-8 weeks of consistent daily use before noticeable changes. The brand's open-label human study (brand-reported results; no placebo group) showed 5.7% average weight loss at 12 weeks and 10.4% at 24 weeks among the 40-participant extension group. Results varied based on lifestyle: participants with healthy diet and regular exercise reported the highest outcomes, while those with average diet and no exercise reported 8.92% - underscoring that lifestyle engagement amplified the supplement's reported effects. Brand-reported body-composition data suggests the majority of loss was attributed to fat rather than lean mass. Buyers should plan for a minimum of 8-12 weeks at the recommended dose before drawing conclusions - keeping in mind that the refund policy does not cover opened bottles regardless of how long they've been in use.
Does Motus contain caffeine or stimulants?
Per the brand's official FAQ and the disclosed formula, Motus is stimulant-free. The brand states it does not rely on caffeine or harsh stimulants. The five disclosed ingredients - Berbevis®, Siliphos®, Alpha-Lipoic Acid, Nicotinamide, and Taurine - are not stimulant compounds. Buyers with sensitivity to stimulants, cardiovascular concerns from prior stimulant use, or experience with sleep disruption from caffeinated fat burners may find this relevant. As always, verify the current label before purchase since formulations can change.
What is Berbevis® and how is it different from regular berberine?
Berbevis® is a branded berberine-phospholipid phytosome manufactured by Indena S.p.A. of Italy. Standard berberine HCL - the form in most berberine supplements - has poor and inconsistent oral bioavailability, meaning much of a standard dose doesn't reach systemic circulation in clinically useful quantities. Berbevis® uses Indena's phytosome technology to bind berberine to a pea protein phospholipid matrix, with Berberis aristata raw extract as the active base and grape seed extract as a GI tolerability protectant. Published pharmacokinetic data from Indena shows Berbevis® delivers higher systemic berberine exposure on a molar basis with dose linearity. Berbevis® also has its own published RCT data showing benefits for measured metabolic markers and body composition versus placebo - a research credential that standard berberine HCL does not have at an equivalent quality level.
Is Motus available on Amazon or through other retailers?
Per the brand's official website, Motus is sold exclusively through the official Tonum website using a direct-to-consumer subscription model. The brand does not list the product as available through Amazon, Walmart, GNC, or other third-party retailers at the time of this writing. Buyers who see Motus on third-party platforms should verify seller identity and authenticity carefully, since the brand's stated distribution model is direct-to-consumer only. Pricing, guarantee terms, and subscription management are confirmed through the official website only.
Final Verdict: What to Verify Before Deciding
Motus is one of the few non-prescription weight-management supplements with a disclosed human clinical study registered on ClinicalTrials.gov, a fully transparent ingredient label with individual doses stated per ingredient, and phytosome-grade ingredient choices that have published pharmacokinetic and clinical literature from Indena S.p.A. Those are genuine differentiators in a category where underdosed proprietary blends and unsupported claims are the norm.
The honest counterweight: the brand's human study is a single open-label trial without a placebo group, and no results are posted in the registry result field at this time - making all outcomes brand-reported. The NCCIH's position on berberine evidence for weight loss remains "not conclusive" at the population level. The refund policy applies only to unopened bottles. The drug interaction profile for berberine in all forms - including Berbevis® - demands a medication review for anyone on prescription medications. And the brand's GLP-1 comparison, while grounded in legitimate differentiating points, should not be read as evidence equivalence between a 100-person open-label study and multi-year randomized controlled trials in thousands of participants.
Before making a decision, verify: current pricing and subscription terms at tonum.com, the current product label for any formula changes since this writing, and drug interactions with any existing medications through a pharmacist review. Those three steps take less time than reading this article and matter more than any single claim in it.
For eligible buyers - adults without the contraindicated medication profiles, not pregnant or nursing, approaching this with calibrated expectations about the pace and magnitude of possible results - Motus is a transparently formulated, non-stimulant metabolic supplement that sits meaningfully above the typical quality floor of its category.
Motus has more clinical backing than most non-prescription weight-management supplements. The evidence supports a cautious trial for eligible buyers. Expectations belong in the range of a promising, research-backed supplement - not a pharmaceutical-grade drug. That honest framing is what the available evidence actually supports.
Review the current Motus formula, pricing, and subscription terms at the official Tonum website
Contact Information
Company: Tonum
Email: [email protected] or [email protected]
Address: Prostasis, LLC 400 North Flagler Drive West Palm Beach, FL 33401 USA
Disclaimers
FDA Disclaimer: The statements in this article have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease. Information provided is for general informational purposes only and does not constitute medical advice. Readers experiencing symptoms or considering changes to their health regimen should consult a licensed healthcare professional. Individual results vary and are not guaranteed.
FTC Affiliate Disclosure: This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products. Disclosure is provided in accordance with FTC 16 CFR Part 255.
FTC Results Variability Disclosure: Customer experiences and study outcomes referenced in this article reflect individual and population-level results. Results vary based on individual factors including age, weight, health status, diet, exercise habits, compliance with recommended dosage, and individual metabolic response. Published study results represent average outcomes in specific study populations and are not a guarantee of results for any individual user.
Medical and Drug Interaction Disclaimer: Motus contains berberine in phytosome form (Berbevis®). Berberine interacts with multiple classes of prescription medications including anticoagulants, diabetes medications, immunosuppressants, and certain cardiovascular medications. Readers currently taking any prescription medication should consult a licensed pharmacist or physician before beginning this or any supplement. Berberine is not appropriate for use during pregnancy or breastfeeding. This article does not constitute medical advice and is not a substitute for professional medical guidance.
Clinical Study Limitations Disclosure: The human clinical study referenced in this article (NCT07152470) is an open-label study sponsored by Prostasis, LLC dba Tonum Health, with no placebo control group and no results currently posted in the registry result field. All outcomes cited are brand-reported. Open-label trial results cannot fully isolate supplement effects from placebo response, behavioral change, or other confounding factors. This study has not been independently replicated in a double-blind, randomized, placebo-controlled design at the time of this writing.
Publisher Independence Statement: This article was produced independently. The publisher is not employed by, not owned by, and not under editorial direction of Tonum Health, Prostasis, LLC, or any of their affiliates. Affiliate compensation does not influence editorial analysis, factual reporting, or the disclosure of product limitations.
Pricing and Availability Disclaimer: Pricing, subscription terms, return policy terms, and product availability are subject to change without notice at the sole discretion of Tonum Health / Prostasis, LLC. Pricing information reflects publicly available data at the time of writing and may not reflect current pricing at the time of reading. Readers should verify current pricing, terms, and availability directly at tonum.com before purchase.
Geographic and Jurisdictional Disclosure: This article is intended for general consumer audiences. Product availability, pricing, and regulatory status may vary by jurisdiction. Buyers outside the United States should verify import regulations, local regulatory classification, and availability in their country of residence before ordering. The brand's official terms of service govern all purchase transactions.
California Consumer Disclosure (Proposition 65): California residents should review the product label and the manufacturer's official website for any warnings required under California's Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65) before purchase. This article is not the seller of the product and does not control the product label; any Prop 65 warning obligation rests with the manufacturer and seller, not with this publication. California consumers with questions about Proposition 65 compliance should contact the manufacturer directly using the contact information on the official website. Information about Proposition 65 is publicly available through the California Office of Environmental Health Hazard Assessment (OEHHA).
Trademark Acknowledgment: Berbevis® and Indena Phytosome® are registered trademarks of Indena S.p.A., Italy. Siliphos® is a registered trademark of Indena S.p.A., Italy. The Motus® product name and associated marks are the property of Tonum Health / Prostasis, LLC. Trademarks referenced in this article are the property of their respective owners; mention does not imply affiliation, endorsement, or sponsorship beyond what is expressly disclosed in the affiliate disclosure block above.
SOURCE: Tonum